Literature DB >> 19265796

Hepatic gene expression in morbidly obese women: implications for disease susceptibility.

Marshall B Elam1, George S Cowan, Robert J Rooney, M Lloyd Hiler, Chandrahasa R Yellaturu, Xiong Deng, George E Howell, Edwards A Park, Ivan C Gerling, Divyan Patel, J Christopher Corton, Lauren M Cagen, Henry G Wilcox, Malay Gandhi, Micheal H Bahr, Micheal C Allan, Linus A Wodi, George A Cook, Thomas A Hughes, Rajendra Raghow.   

Abstract

The objective of this study was to determine the molecular bases of disordered hepatic function and disease susceptibility in obesity. We compared global gene expression in liver biopsies from morbidly obese (MO) women undergoing gastric bypass (GBP) surgery with that of women undergoing ventral hernia repair who had experienced massive weight loss (MWL) following prior GBP. Metabolic and hormonal profiles were examined in MO vs. MWL groups. Additionally, we analyzed individual profiles of hepatic gene expression in liver biopsy specimens obtained from MO and MWL subjects. All patients underwent preoperative metabolic profiling. RNAs were extracted from wedge biopsies of livers from MO and MWL subjects, and analysis of mRNA expression was carried out using Affymetrix HG-U133A microarray gene chips. Genes exhibiting greater than twofold differential expression between MO and MWL subjects were organized according to gene ontology and hierarchical clustering, and expression of key genes exhibiting differential regulation was quantified by real-time-polymerase chain reaction (RT-PCR). We discovered 154 genes to be differentially expressed in livers of MWL and MO subjects. A total of 28 candidate disease susceptibility genes were identified that encoded proteins regulating lipid and energy homeostasis (PLIN, ENO3, ELOVL2, APOF, LEPR, IGFBP1, DDIT4), signal transduction (MAP2K6, SOCS-2), postinflammatory tissue repair (HLA-DQB1, SPP1, P4HA1, LUM), bile acid transport (SULT2A, ABCB11), and metabolism of xenobiotics (GSTT2, CYP1A1). Using gene expression profiling, we have identified novel candidate disease susceptibility genes whose expression is altered in livers of MO subjects. The significance of altered expression of these genes to obesity-related disease is discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19265796     DOI: 10.1038/oby.2009.49

Source DB:  PubMed          Journal:  Obesity (Silver Spring)        ISSN: 1930-7381            Impact factor:   5.002


  18 in total

1.  Hepatic gene networks in morbidly obese patients with nonalcoholic fatty liver disease.

Authors:  Samer Gawrieh; Tesfaye M Baye; Melanie Carless; James Wallace; Richard Komorowski; David E Kleiner; Deborah Andris; Bassem Makladi; Regina Cole; Michael Charlton; Joanne Curran; Thomas D Dyer; Jac Charlesworth; Russell Wilke; John Blangero; Ahmed H Kissebah; Michael Olivier
Journal:  Obes Surg       Date:  2010-12       Impact factor: 4.129

2.  Nutritional strategy to prevent fatty liver and insulin resistance independent of obesity by reducing glucose-dependent insulinotropic polypeptide responses in mice.

Authors:  Farnaz Keyhani-Nejad; Martin Irmler; Frank Isken; Eva K Wirth; Johannes Beckers; Andreas L Birkenfeld; Andreas F H Pfeiffer
Journal:  Diabetologia       Date:  2014-10-28       Impact factor: 10.122

3.  Insulin induces REDD1 expression through hypoxia-inducible factor 1 activation in adipocytes.

Authors:  Claire Regazzetti; Frédéric Bost; Yannick Le Marchand-Brustel; Jean-François Tanti; Sophie Giorgetti-Peraldi
Journal:  J Biol Chem       Date:  2009-12-08       Impact factor: 5.157

4.  Regulated in Development and DNA Damage Responses 1 Prevents Dermal Adipocyte Differentiation and Is Required for Hair Cycle-Dependent Dermal Adipose Expansion.

Authors:  Guillermo C Rivera-Gonzalez; Anna Klopot; Kaitlyn Sabin; Gleb Baida; Valerie Horsley; Irina Budunova
Journal:  J Invest Dermatol       Date:  2020-02-04       Impact factor: 8.551

5.  Hepatic gene expression profiling reveals key pathways involved in leptin-mediated weight loss in ob/ob mice.

Authors:  Ashok Sharma; Shoshana M Bartell; Clifton A Baile; Bo Chen; Robert H Podolsky; Richard A McIndoe; Jin-Xiong She
Journal:  PLoS One       Date:  2010-08-16       Impact factor: 3.240

6.  Aberrant REDD1-mTORC1 responses to insulin in skeletal muscle from Type 2 diabetics.

Authors:  David L Williamson; Cory M Dungan; Abeer M Mahmoud; Jacob T Mey; Brian K Blackburn; Jacob M Haus
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-08-12       Impact factor: 3.619

7.  Genome-wide analysis of hepatic lipid content in extreme obesity.

Authors:  Johanna K DiStefano; Christopher Kingsley; G Craig Wood; Xin Chu; George Argyropoulos; Christopher D Still; Stefania Cotta Doné; Christophe Legendre; Waibhav Tembe; Glenn S Gerhard
Journal:  Acta Diabetol       Date:  2014-09-23       Impact factor: 4.280

8.  A microbial metabolite remodels the gut-liver axis following bariatric surgery.

Authors:  Snehal N Chaudhari; James N Luo; David A Harris; Hassan Aliakbarian; Lina Yao; Donggi Paik; Renuka Subramaniam; Arijit A Adhikari; Ashley H Vernon; Ayse Kiliç; Scott T Weiss; Jun R Huh; Eric G Sheu; A Sloan Devlin
Journal:  Cell Host Microbe       Date:  2021-01-11       Impact factor: 21.023

9.  ENO3 promoted the progression of NASH by negatively regulating ferroptosis via elevation of GPX4 expression and lipid accumulation.

Authors:  Di Lu; Qiaoyun Xia; Zhiyu Yang; Shanjun Gao; Suofeng Sun; Xiaoying Luo; Zhen Li; Xiulei Zhang; Shuangyin Han; Xiuling Li; Mingbo Cao
Journal:  Ann Transl Med       Date:  2021-04

10.  Dysregulation of sterol regulatory element binding protein-1c in livers of morbidly obese women is associated with altered suppressor of cytokine signaling-3 and signal transducer and activator of transcription-1 signaling.

Authors:  Marshall B Elam; Chandrahasa Yellaturu; George E Howell; Xiong Deng; George S Cowan; Poonam Kumar; Edwards A Park; M Lloyd Hiler; Henry G Wilcox; Thomas A Hughes; George A Cook; Rajendra Raghow
Journal:  Metabolism       Date:  2009-11-14       Impact factor: 8.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.